Patents by Inventor Charles W. Henry
Charles W. Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12226450Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: GrantFiled: July 1, 2022Date of Patent: February 18, 2025Assignees: OP-T LLC, The Regents of the University of Colorado, A Body CorporateInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20250018012Abstract: Methods and compositions are disclosed for treating and preventing cytokine release syndrome (CRS). acute respiratory distress syndrome (CRS), and alveolar capillary injury (ACI) in a subject.Type: ApplicationFiled: June 18, 2024Publication date: January 16, 2025Inventors: David H. Wagner, JR., Gisela M. Vaitaitis, Charles W. Henry, Martin Glenn Yussman
-
Publication number: 20240374686Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to B-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: ApplicationFiled: July 30, 2024Publication date: November 14, 2024Inventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
-
Patent number: 12048734Abstract: Methods and compositions are disclosed for treating and preventing cytokine release syndrome (CRS), acute respiratory distress syndrome (CRS), and alveolar capillary injury (ACI) in a subject.Type: GrantFiled: April 16, 2021Date of Patent: July 30, 2024Assignee: OP-T LLCInventors: David H. Wagner, Jr., Gisela M. Vaitaitis, Charles W. Henry, Martin G. Yussman
-
Patent number: 12005151Abstract: An integrated light device for invocation from a smartphone includes an antimicrobial light wavelength emanating from a utility light portal of the smartphone. Antimicrobial light, such as those in the so-called UVC range (about 222 nm wavelength) have been shown to effectively decontaminate irradiated surfaces against COVID-19 and other harmful depositions on the surfaces, with minimal harmful radiation to humans. Replacing or controlling a smartphone utility light, such as the LED responsive to a “flashlight” function, allows the personal device to be invoked to quickly irradiate surfaces prior to use, such as sitting, eating, opening doors, and the like.Type: GrantFiled: August 24, 2022Date of Patent: June 11, 2024Assignee: Luminary, LLCInventors: Adam E. M. Eltorai, Charles W. Henry
-
Publication number: 20240115651Abstract: Methods and materials for treating and preventing autoimmune diseases, in particular, multiple sclerosis (MS) including small peptides are capable of interacting with CD40, thereby altering and/or modulating the ability of CD40 to interact with CD154, which apparently affects inflammation; and/or the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response; and/or the use of such short peptides to prevent or reverse autoimmune disease, and particularly, multiple sclerosis, in individuals; and/or methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. Additionally, methods and apparatuses to administer the peptide are provided.Type: ApplicationFiled: September 14, 2023Publication date: April 11, 2024Inventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis
-
Patent number: 11793854Abstract: Methods and materials for treating and preventing autoimmune diseases, in particular, multiple sclerosis (MS) including small peptides are capable of interacting with CD40, thereby altering and/or modulating the ability of CD40 to interact with CD154, which apparently affects inflammation; and/or the use of such peptides in reducing the inflammatory response, and in particular, the autoimmune inflammatory response; and/or the use of such short peptides to prevent or reverse autoimmune disease, and particularly, multiple sclerosis, in individuals; and/or methods and materials for detecting T-cells that express CD40 (Th40 cells). Also provided are kits for reducing inflammation, treating autoimmune diseases, or detecting Th40 cells. Additionally, methods and apparatuses to administer the peptide are provided.Type: GrantFiled: March 23, 2020Date of Patent: October 24, 2023Assignee: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis
-
Patent number: 11744875Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: GrantFiled: July 13, 2020Date of Patent: September 5, 2023Assignee: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20230101772Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: ApplicationFiled: July 1, 2022Publication date: March 30, 2023Inventors: David H. Wagner, Jr., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20230055664Abstract: An integrated light device for invocation from a smartphone includes an antimicrobial light wavelength emanating from a utility light portal of the smartphone. Antimicrobial light, such as those in the so-called UVC range (about 222 nm wavelength) have been shown to effectively decontaminate irradiated surfaces against COVID-19 and other harmful depositions on the surfaces, with minimal harmful radiation to humans. Replacing or controlling a smartphone utility light, such as the LED responsive to a “flashlight” function, allows the personal device to be invoked to quickly irradiate surfaces prior to use, such as sitting, eating, opening doors, and the like.Type: ApplicationFiled: August 24, 2022Publication date: February 23, 2023Inventors: Adam E.M. Eltorai, Charles W. Henry
-
Publication number: 20220288254Abstract: A light-based sterilization source directs a blue light at a touched or contacted surface for eliminating harmful viral or bacterial contaminants. The blue light is outside the range of harmful UV light while delivering an effective decontaminating light source for eradication of pathogenic microorganisms. An irradiation device includes a light source disposed for irradiating a bathroom or fixture surface for sterilization. A corresponding system for sterilization of contaminated surfaces using the irradiation device includes a blue light source having a wavelength outside a harmful spectrum such as the UV (ultraviolet) spectrum.Type: ApplicationFiled: March 14, 2022Publication date: September 15, 2022Inventors: Adam E. M. Eltorai, Charles W. Henry
-
Publication number: 20220183584Abstract: Methods, devices and systems for location of the disposition of a medical probe in a subject are disclosed. An array of electromagnetic drive coil sets, each having two or three dimensionally oriented drive coils, a sensor coil being electromagnetically communicative with the array of electromagnetic drive coil sets, a discrete core wire providing response to electrical stimuli of the subject, and a controller communicative with and adapted to energize one or more of the electromagnetic coils in the array of electromagnetic drive coil sets are disclosed. Energizing of the one or more of the electromagnetic coils including one or more of energizing the coils singly, or in pairs of x-y and y-z or x-z coils while measuring the response of the sensor coil, whereby the system uses the measurements of the responses of the sensor coil to calculate the location of the sensor coil relative to said drive coil sets.Type: ApplicationFiled: September 21, 2021Publication date: June 16, 2022Inventors: Peter E. NELSON, Robert D. ZELLERS, Charles W. HENRY
-
Publication number: 20220062478Abstract: A light-based sterilization source directs an antimicrobial light at a touched or contacted surface for eliminating harmful viral or bacterial contaminants. The antimicrobial light is outside the range of harmful UV light while delivering an effective decontaminating light source for eradication of pathogenic microorganisms. An acrylic or other transparent medium conducts the antimicrobial light from a source to an irradiated target surface for continual decontamination, and may define a backlighting arrangement.Type: ApplicationFiled: September 2, 2021Publication date: March 3, 2022Inventors: Adam E. M. Eltorai, Charles W. Henry
-
Publication number: 20220031632Abstract: The present developments provide methods and compositions for treating and/or preventing autoimmune diseases. In certain aspects, the present disclosure relates to the use of short peptides loaded inside of nanoparticle nanospheres, nanocapsules, or PEGylated nanoparticles. Additionally, peptide-metal nanoparticle drug conjugates are described and disclosed. In some embodiments, these nanoparticles, whether polymer based or metal-conjugated, when linked or coupled to bioactive peptides provided herein, may be capable of interacting with CD40 proteins or CD40 complexes, and thereby may interfere with the ability of CD40 to interact with CD154. The present disclosure also relates to the use of such nanoparticle-peptide conjugates in reducing the inflammatory response, and in particular, the autoimmune inflammatory response.Type: ApplicationFiled: May 14, 2021Publication date: February 3, 2022Inventors: David H. Wagner, JR., Martin G. Yussman, Gisela M. Vaitaitis, Charles W. Henry
-
Publication number: 20220000979Abstract: Methods and compositions are disclosed for treating and preventing cytokine release syndrome (CRS), acute respiratory distress syndrome (CRS), and alveolar capillary injury (ACI) in a subject.Type: ApplicationFiled: April 16, 2021Publication date: January 6, 2022Inventors: David H. Wagner, JR., Gisela M. Vaitaitis, Charles W. Henry, Martin G. Yussman
-
Publication number: 20210332104Abstract: Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and/or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof.Type: ApplicationFiled: July 1, 2021Publication date: October 28, 2021Inventors: David H. Wagner Jr., Martin G. Yussman, Charles W. Henry
-
Patent number: 11150207Abstract: Methods, devices and systems for three-dimensional location of the disposition of a sensor coil in a subject including are disclosed. The systems include an array of three or more triplet or quadruplet drive coil sets, at least one moveable sensor coil configured to be disposed in a subject and to provide one or more sensor coil response signals responsive to the respective electromagnetic wave fields, a receiving component configured to control drive signals to the array of drive coil sets and to measure sensor coil response signals from the moveable sensor coil, and a processor is configured to determine a sensor coil disposition in the subject relative to said triplet or quadruplet drive coil sets. The receiving component provides a modified drive signal to maximize or optimize the generated respective electromagnetic wave fields, or the one or more sensor coil response signals.Type: GrantFiled: November 5, 2018Date of Patent: October 19, 2021Assignee: TELEFLEX LIFE SCIENCES LIMITEDInventors: Peter E. Nelson, Robert D. Zellers, Charles W. Henry
-
Patent number: 11122991Abstract: Methods, devices and systems for location of the disposition of a medical probe in a subject are disclosed. An array of electromagnetic drive coil sets, each set having two or three dimensionally oriented drive coils, a sensor coil being electromagnetically communicative with the array of electromagnetic drive coil sets, a discrete core wire providing response to electrical stimuli of the subject, and a system controller communicative with and adapted to energize one or more of the electromagnetic coils in the array of electromagnetic drive coil sets are disclosed. The energizing of the one or more of the electromagnetic coils including one or more of energizing the coils singly, or in pairs of x-y and y-z or x-z coils while measuring the response of the sensor coil, whereby the system uses the measurements of the responses of the sensor coil to calculate the location of the sensor coil relative to said drive coil sets.Type: GrantFiled: October 15, 2018Date of Patent: September 21, 2021Assignee: TELEFLEX LIFE SCIENCES LIMITEDInventors: Peter E. Nelson, Robert D. Zellers, Charles W. Henry
-
Publication number: 20210008162Abstract: Bioactive peptides and methods for their use for preventing, treating, and/or reducing the incidence and/or symptoms of an autoimmune disease or disorder that may result from chronic inflammation, damage to ?-cells of the pancreas, and other conditions that are implicated by the CD40-CD154 dyad. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation, autoimmunity, and disease progression. The use of such peptides in reducing diabetes mellitus, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. Methods and materials for preventing and modulating diabetes mellitus and autoimmune diseases especially in dogs, cats, and horses.Type: ApplicationFiled: July 13, 2020Publication date: January 14, 2021Applicant: OP-T LLCInventors: David Hal Wagner, JR., Martin Glenn Yussman, Charles W. Henry
-
Publication number: 20200326333Abstract: Methods and cellular markers useful for methods of diagnosing autoimmune disease, including type 1 diabetes (T1D) and disease progression in T1D patients, as well as identifying treatments for and monitoring treatment of patients with T1D. Methods of treating patients having T1D.Type: ApplicationFiled: April 10, 2020Publication date: October 15, 2020Applicant: OP-T LLCInventors: David Hal Wagner, Jr., Martin Glenn Yussman, Charles W. Henry, Gisela M. Vaitaitis